Navigation Links
Glycominds and Fox Chase Cancer Center Announce a Collaboration to Discover New Cancer Detection Diagnostic Tests
Date:10/25/2007

LOD, Israel, October 25 /PRNewswire/ -- Glycominds Ltd., a bio-diagnostics company specializing in glycan biomarkers for diagnosis and disease management of autoimmune diseases and cancer, announced today entering into a research agreement with Fox Chase Cancer Center (FCCC), an NCI designated cancer center to develop a new diagnostics blood test for breast cancer.

"We are very pleased to work with FCCC on this project," stated Dr. Nir Dotan, Glycominds' co-founder, CTO and VP R&D. "Glycominds' anti-glycan antibodies biomarkers approach together with the FCCC excellent patient records, samples and clinical know-how give this project a high basis for success."

"Glycominds' glycan biomarker technology stands out as innovative and unique. We hope that just as Glycominds was able to successfully develop new diagnostic and prognostic biomarkers for Autoimmune disorders, we will be able to identify glycans that can be useful in the early detection of cancer," stated Dr. Andrew K. Godwin, FCCC's Director of the Clinical Molecular Genetics Laboratory and the Biosample Repository . "I believe that glycan technology has the potential to enhance the early diagnosis of breast cancer and improve the health and quality of life for millions of women."

About Glycominds Ltd.

Glycominds Ltd. is a biodiagnostics company specialized in developing and commercializing glycan biomarkers, a new class of early diagnostic and prognostic tests based on complex sugar molecules for the detection and management of autoimmune diseases and cancer. The company's goal is to provide physicians with tools that improve treatment selection in autoimmune diseases and early detection of cancers.

Glycominds lead product, IBDX(R), a blood test for early diagnosis of Inflammatory Bowel Disease (IBD) and the prognosis of Crohn's disease severity is commercialized in Israel and Europe, with a U.S. launch planned in early 2008. The Company's gMS(TM) Dx, a blood test for early diagnosis of Multiple Sclerosis (MS), and gMS(TM) PRO, a prognostic test for MS activity, are also expected to enter the market in 2008. Glycominds' other pipeline products include blood tests for the prediction of recurrent pregnancy loss based on hyper-coagulation caused by antiphoshpholipids syndrome (APS), and first-in-class screening tests for breast and colorectal cancers. http://www.glycominds.com

For more information, please contact:

Glycominds, Ltd.

Dr. Avinoam Dukler

Chief Executive Officer

dukler@glycominds.com

The Ruth Group

Sara Ephraim (investors)

Phone: +1-646-536-7002

sephraim@theruthgroup.com

Janine McCargo (media)

Phone: +1-646-536-7033

jmccargo@theruthgroup.com


'/>"/>
SOURCE Glycominds Ltd.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Purchase of Madison broadband network may bring improved service
2. Wisconsin fares slightly better in venture capital chase
3. Metavante completes purchase of check processing firm
4. Logicalis purchases Solution Technology for $90M
5. Merge eFilm announces stock repurchase plan
6. Wisconsin based Graphics Distribution, Inc. purchased by Florida company
7. GE Medicals Acquisitions May Prompt More Purchases
8. Green Bay Software Company Purchased by GE
9. Tissue Specificity for Mutation Parallels Tissue Specificity for Cancer
10. Cancer siRNA Oligo Set Version 1.0
11. Cancer-Related miRNAs Uncovered by the mirVana miRNA Microarray Platform
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... ... its endogenous context, enabling overexpression experiments and avoiding the use of exogenous expression ... guides is transformative for performing systematic gain-of-function studies. , This complement to ...
(Date:10/11/2017)... a leading provider of patient support solutions, has announced the ... which will launch this week. The VMS CNEs will address ... enhance the patient care experience by delivering peer-to-peer education programs ... to help women who have been diagnosed and are being ... ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... has granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer and ... of osteosarcoma. SBT-100 is able to cross the cell membrane and bind intracellular ...
(Date:10/10/2017)... ... October 10, 2017 , ... Dr. Bob Harman, founder ... local San Diego Rotary Club. The event entitled “Stem Cells and ... had 300+ attendees. Dr. Harman, DVM, MPVM was joined by two human doctors: ...
Breaking Biology Technology:
(Date:4/24/2017)... , April 24, 2017 Janice ... partner with  Identity Strategy Partners, LLP (IdSP) , ... or without President Trump,s March 6, 2017 ... Entry , refugee vetting can be instilled with greater ... (Right now, all refugee applications are suspended by ...
(Date:4/18/2017)... 2017  Socionext Inc., a global expert in SoC-based imaging and ... the M820, which features the company,s hybrid codec technology. A demonstration ... Probe, Inc., will be showcased during the upcoming Medtec Japan at ... the Las Vegas Convention Center April 24-27. ... Click here for an ...
(Date:4/13/2017)... Calif. , April 13, 2017 UBM,s ... York will feature emerging and evolving technology ... Both Innovation Summits will run alongside the expo portion ... speaker sessions, panels and demonstrations focused on trending topics ... largest advanced design and manufacturing event will take place ...
Breaking Biology News(10 mins):